Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review.

The reviewed evidence suggests that bisphosphonate treatments are cost-effective options for bone metastases, while denosumab is unlikely to represent value for money. Evidence on EBR and Sr89 is limited and less conclusive.